Editorial – Metronomic chemotherapy

Since cytotoxic drugs are neither specific nor targeted to the cancer cells, significant research has focused on improved delivery of these drugs to tumor tissues with limited success. A search for the keyword “metronomic” identified about 172 clinical trials in various cancers, where a combination...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2017-08, Vol.400, p.203-203
Main Authors: Kumar, M.N.V. Ravi, PhD, Sood, Anil K., MD
Format: Article
Language:English
Subjects:
Administration, Metronomic
Animals
Antineoplastic Agents - administration & dosage
Bevacizumab
Cancer
Chemotherapy
Clinical trials
Cyclophosphamide
Cytotoxicity
Drug delivery
Drug dosages
Folkman, Judah
Hematology, Oncology and Palliative Medicine
Humans
Methotrexate
Monoclonal antibodies
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Paclitaxel
Targeted cancer therapy
Tissues
Trastuzumab
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since cytotoxic drugs are neither specific nor targeted to the cancer cells, significant research has focused on improved delivery of these drugs to tumor tissues with limited success. A search for the keyword “metronomic” identified about 172 clinical trials in various cancers, where a combination of small molecule drugs administered in metronomic regimen (e.g., cyclophosphamide; methotrexate; paclitaxel) or small molecule drugs administered in metronomic regimen combined with standard biologic therapies (e.g., bevacizumab; pertuzumab; trastuzumab) (clinical...
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2017.03.003